Aligos Therapeutics, Inc.
ALGS
$7.50
$0.162.18%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -19.88M | -31.54M | -15.86M | 43.09M | -82.15M |
| Total Depreciation and Amortization | 257.00K | 220.00K | 259.00K | 194.00K | 241.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 293.00K | 5.44M | -830.00K | -60.36M | 63.90M |
| Change in Net Operating Assets | -2.41M | 1.53M | 930.00K | -3.84M | -390.00K |
| Cash from Operations | -21.75M | -24.35M | -15.50M | -20.91M | -18.40M |
| Capital Expenditure | -92.00K | -193.00K | -109.00K | -43.00K | -28.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1.93M | 47.88M | -39.31M | -44.02M | 20.00M |
| Cash from Investing | -2.02M | 47.68M | -39.42M | -44.07M | 19.97M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -3.00K | -10.00K | -1.00K | -- | -43.00K |
| Issuance of Common Stock | 126.00K | -- | -- | 101.74M | 140.00K |
| Repurchase of Common Stock | -- | -43.00K | -176.00K | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 123.00K | -53.00K | -177.00K | 101.74M | 97.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -23.64M | 23.29M | -55.10M | 36.77M | 1.67M |